Blood Test Plus Gene Screen Narrows Alzheimer's Symptom Clock to a Few Years

A pooled analysis of more than 8,500 people without symptoms finds that adding APOE genotype to a plasma p-tau217 reading sharpens predictions of when cognitive symptoms will appear, the next step from the p-tau217 blood test cleared by regulators earlier this year.

Researchers led by Columbia University report that combining a blood test for phosphorylated tau 217 (p-tau217) with APOE genotyping narrows the predicted window for Alzheimer's symptom onset in people who currently show no symptoms. In a pooled analysis of participant-level data from 8,582 adults across seven cohorts in the United States, Canada and the Dominican Republic, published online September 9, 2026, in The Lancet Neurology, the team found that once plasma p-tau217 became elevated, people carrying one or more copies of the APOE4 variant tended to develop symptoms within three to four years, while those with other APOE genotypes tended to develop symptoms within five to six years.

The finding builds on the plasma p-tau217 blood test this paper has already covered, including its clearance for adults as young as 40. That test measures a protein fragment tied to the buildup of amyloid and tau in the brain and can turn positive years before memory problems appear, but on its own it has told clinicians only that risk is elevated, not when to expect symptoms. The new analysis, led by Yuexuan Xu and colleagues including Columbia neurology chair Richard Mayeux, sought to test whether APOE status, a well established genetic risk factor for Alzheimer's, could sharpen that timing estimate once p-tau217 crosses into abnormal range.

The study pooled data from cohorts including the Washington Heights-Inwood Columbia Aging Project, the Alzheimer's Disease Neuroimaging Initiative, the Wisconsin Registry for Alzheimer's Prevention and others, and the authors report that the projected timing held across the different racial and ethnic groups represented, which included non-Hispanic white, Black and Caribbean Hispanic participants. The authors describe the work as pooled observational data, not a clinical trial, and say the combined marker could eventually help time enrollment in prevention trials or the prescribing of drugs now in development, a decision they stress belongs to physicians, not to the blood test alone.

The study's own limitations, noted in the paper, include that most cohorts measured p-tau217 at only a single point in time rather than repeatedly, that assay platforms and follow-up periods differed across cohorts, and that the outcome measure combined multiple forms of cognitive impairment rather than confirmed Alzheimer's disease alone.

The authors say further work with repeated biomarker measurements and longer, harmonized follow-up will be needed before the combined test could be used to time individual treatment decisions.